the Developments on Therapeutic Approaches for COVID-19
DOI:
https://doi.org/10.53089/medula.v11i2.312Abstract
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.
References
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak J Autoimmun. 2020;109:102433. doi: 10. 1016/j.jaut.2020.102433
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71–6. doi: 10.1016/j.ijsu.2020.02.034Kjfkf
LiQ,GuanX,WuP,WangX,ZhouL, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus- infected pneumonia. N Engl J Med. 2020; 382:1199–207. doi: 10.1056/NEJMoa200 1316
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565– 74. doi: 10.1016/S0140-6736(20)30251-8
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14 (1):58–60. doi: 10.5582/ddt.2020.01012
Kementerian Kesehatan. (2020). Peta Sebaran COVID-19. Diunduh pada tanggal 20 April 2020 melalui website : https://covid19.go.id/
World Health Organization/ WHO. (2021). Diunduh pada tanggal 25 Juni 2021 melalui website : https://covid19.who.int/Rrr
CDC. 2021a. COVID-19 and Your Health [Online]. Available: https://www.cdc.go v/coronavirus/2019 -ncov/your- health/index.html [Accessed 23 Juli 2021]
Zhu, Guan X, Li Y, Huang JY, Jiang T, Hou LH et al. 2020a. Immunogenicity and safety of a recombinant adenovirus type-5- vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 396, 479- 488.
Drosten, Ghunter S, Preiser W, Van DW, Brodht HR, Becker et al. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med, 348, 1967-76.
Zaki, Van BS, Bestebroer T, M Osterhaus, Fouchier RA. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl JMed, 367, 1814-20
Rothan and Byrareddy SN. 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun, 109, 102433.
Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019)- Recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11. doi: 10.26355/ eurrev_202002_20378
Mouffak S, Shubbar Q, Saleh E, Awady ER. Recent Advances in Management of Covid-19: A Review. J Biomedicine.2021; https://doi.org/10.1016/j.biopha.2021.112107
National Guidelines for Clinical Management and Treatment of COVID-19. 2020 1 June.
Cohen P., Blau J., Bloom A. COVID-19: Outpatient evaluation and management of acute illness in adults.
S Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 a (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895–902. https://doi.org/10.1016/j.vaccine.2010.0
Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. https://doi.org/ 10.1016/s0140-6736(15)60454-8.
Daczkowski CM, Dzimianski JV, Clasman JR, Goodwin O, Mesecar AD, Pegan SD. Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species. J Mol Biol. 2017;429(11):1661–83. doi: 10.101 6/j.jmb.2017.04.011
Perhimpunan Dokter Paru Indonesia. Pneumonia COVID-19: Diagnosis & penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2020.
Direktorat Jenderal Pencegahan dan Pengendalian Penyakit–Kementerian Kesehatan Republik Indonesia. Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19) Jakarta: Kementerian Kesehatan Republik Indonesia; Maret 2020
Tan ELC, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerging Infectious Diseases. 2004;10(4): 581–6. doi: 10.3201/eid1004.030458
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020; 323(11):1061–9. doi: 10.1001/jama.2020. 1585
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-0
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;ciaa237. doi: 10.1093/cid/ciaa2 37
Chan KW, Wong VT, Tang SCW. COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020;48(3):737–62. doi: 10.1142/S01924 15X20500378
Voysey, Merryn, Sue Ann Costa Clemens, Shabir A. Madhi, Lily Y. Weckx, Pedro M. Folegatti, Parvinder K. Aley, Brian Angus, et al. 2021. ―Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four RandomisedControlled Trials in Brazil, South Africa, and the UK.‖ The Lancet397 (10269): 99–111. https://doi.org/10.1016/S0140-6736(20)3266
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
